Home Cart Sign in  
Chemical Structure| 18683-91-5 Chemical Structure| 18683-91-5

Structure of Ambroxol
CAS No.: 18683-91-5

Chemical Structure| 18683-91-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus.

Synonyms: NA-872

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ambroxol

CAS No. :18683-91-5
Formula : C13H18Br2N2O
M.W : 378.10
SMILES Code : O[C@H]1CC[C@H](NCC2=CC(Br)=CC(Br)=C2N)CC1
Synonyms :
NA-872
MDL No. :MFCD00242702

Safety of Ambroxol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P280-P305+P351+P338-P310

Isoform Comparison

Biological Activity

Target
  • Sodium Channel

    Sodium channel, IC50:35.2 μM-22.5 μM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02373891 Healthy Volunteers Phase 1 Completed - -
NCT03177889 Bronchiectasis Adult ... More >> Traditional Chinese Medicine Quality of Life Exacerbation Less << Not Applicable Not yet recruiting December 31, 2019 -
NCT02395913 Healthy Male Phase 1 Completed - -
NCT02036775 Healthy Phase 1 Completed - Russian Federation ... More >> 18.510.2 Boehringer Ingelheim Investigational Site St. Petersburg, Russian Federation Less <<
NCT00148499 Pharyngitis Phase 3 Completed - Romania ... More >> Medicover Bucharest, Romania, 010224 Medicover Bucharest, Romania, 010626 Medicover Bucharest, Romania, 021106 Victor Babes Clincial Hospital Bucharest, Romania, 030303 Ukraine Regional Student Hospital Kharkov, Ukraine, 61002 Regional Clinical Hospital Kharkov, Ukraine, 61022 City Clinical Otolaryngological Hospital Kharkov, Ukraine, 61024 City Clinical Hospital No. 17 Kharkov, Ukraine, 61037 City Clinical Hospital No. 11 Kharkov, Ukraine, 61050 City Clinical Hospital No. 26 Kharkov, Ukraine, 61072 Academy of Medical Science named after O.S. Kolomyichenko Kiev, Ukraine, 03057 City Clinical Hospital No. 9 Kiev, Ukraine, 04112 City Clinical Hospital No. 11 Odessa, Ukraine, 65006 Regional Clinical Hospital Zaporozhye, Ukraine, 69600 Less <<
NCT00525044 Pharyngitis Phase 3 Completed - China ... More >> Boehringer Ingelheim Investigational Site Nanjing, China Boehringer Ingelheim Investigational Site Shanghai, China ENT Subsidiary of Fudan University Hospital Shanghai, China Boehringer Ingelheim Investigational Site Wuhan, China Less <<
NCT01713179 In the Present Study, we Inves... More >>tigated the Effects of Oral Ambroxol on Tear Film and Ocular Surface. Less << Phase 1 Phase 2 Completed - Korea, Republic of ... More >> Hallym University, Kangnam Sacred Heart Hospital Seoul, Korea, Republic of, 150-950 Less <<
NCT00144274 Pharyngitis Phase 3 Completed - South Africa ... More >> Boehringer Ingelheim Investigational Site Boksburg, South Africa, 1461 Boehringer Ingelheim Investigational Site Cape Town, South Africa, 7646 Boehringer Ingelheim Investigational Site Cape Town, South Africa, 7700 Boehringer Ingelheim Investigational Site Cape Town, South Africa, 7945 Boehringer Ingelheim Investigational Site Durban, South Africa, 4091 Boehringer Ingelheim Investigational Site Johannesburg, South Africa, 2033 Boehringer Ingelheim Investigational Site Johannesburg, South Africa, 2192 Boehringer Ingelheim Investigational Site Krugersdorp, South Africa, 1739 Boehringer Ingelheim Investigational Site Midrand, South Africa, 1685 Boehringer Ingelheim Investigational Site Pretoria, South Africa, 0038 Boehringer Ingelheim Investigational Site Pretoria, South Africa, 0157 Boehringer Ingelheim Investigational Site Sandton, South Africa, 2021 Less <<
NCT02036775 - Completed - -
NCT02194257 Healthy Phase 1 Completed - -
NCT02572609 Healthy Phase 1 Completed - -
NCT02194283 Healthy Phase 1 Completed - -
NCT02194270 Healthy Phase 1 Completed - -
NCT02572609 - Completed - -
NCT03583658 Pharyngitis Phase 3 Completed - South Africa ... More >> Investigational Site Number 7100005 Johannesburg, South Africa Less <<
NCT01361802 Pharyngitis P... More >>ain Less << Phase 2 Completed - South Africa ... More >> 18.504.27015 Boehringer Ingelheim Investigational Site Bloemfontein, South Africa 18.504.27005 Boehringer Ingelheim Investigational Site Cape Town, South Africa 18.504.27011 Boehringer Ingelheim Investigational Site Cape Town, South Africa 18.504.27013 Boehringer Ingelheim Investigational Site Cape Town, South Africa 18.504.27014 Boehringer Ingelheim Investigational Site Cape Town, South Africa 18.504.27008 Boehringer Ingelheim Investigational Site Durban, South Africa 18.504.27010 Boehringer Ingelheim Investigational Site Durban, South Africa 18.504.27001 Boehringer Ingelheim Investigational Site Johannesburg, South Africa 18.504.27004 Boehringer Ingelheim Investigational Site Klipspruit West, South Africa 18.504.27003 Boehringer Ingelheim Investigational Site Krugersdorp, South Africa 18.504.27002 Boehringer Ingelheim Investigational Site Lenasia, South Africa 18.504.27006 Boehringer Ingelheim Investigational Site Newtown, South Africa 18.504.27012 Boehringer Ingelheim Investigational Site Paarl, South Africa 18.504.27007 Boehringer Ingelheim Investigational Site Pretoria, South Africa 18.504.27009 Boehringer Ingelheim Investigational Site Sydenham, South Africa Less <<
NCT01573663 Healthy Phase 1 Completed - Korea, Republic of ... More >> Samsung medical center Seoul, Korea, Republic of Less <<
NCT02914366 Parkinson's Disease Dementia Phase 2 Recruiting December 2018 Canada, Ontario ... More >> Parkwood Institute Recruiting London, Ontario, Canada, N6C 0A7 Contact: Carolina Silveira, Ph.D    519-646-6100 ext 42367    Carolina.Silveira@sjhc.london.on.ca    Contact: Tommy Li, MSc    519-646-6100 ext 42711    Zhonghan.Li@sjhc.london.on.ca Less <<
NCT02194296 Healthy Phase 1 Completed - -
NCT02941822 Parkinson Disease PHASE2 COMPLETED 2025-05-18 Leonard Wolfson Experimental N... More >>eurology Centre Clinical Research Facility LWENC CRF, London, United Kingdom Less <<
NCT03415269 Cough Phase 2 Not yet recruiting May 2018 United Kingdom ... More >> Castle Hill Hospital Cottingham, East Yorkshire, United Kingdom, HU16 5JQ Less <<
NCT01463215 Type I Gaucher Disease PHASE1|PHASE2 SUSPENDED 2025-08-15 ExSAR Corporation, Monmouth Ju... More >>nction, New Jersey, 08852, United States Less <<
NCT03950050 Gaucher Disease, Type 1 PHASE2 COMPLETED 2022-12-30 Shaare Zedek Medical Center, J... More >>erusalem, Israel Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.64mL

0.53mL

0.26mL

13.22mL

2.64mL

1.32mL

26.45mL

5.29mL

2.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories